Available Technologies

ADDITIONAL FILTERS

Diagnostics

36 available technologies

Direct Profiling of Proteins in Diseased Tissue by Mass Spectrometry for Assessment of Disease Classification, Development and Treatment

Methods and apparatuses for analyzing proteins and other biological materials and xenobiotics within a sample. A specimen is generated, which may include an energy absorbent matrix. The specimen is struck with laser beams such that the specimen releases proteins. The atomic mass of the released proteins over a range of atomic masses is measured. An atomic mass window of interest within the range of atomic masses is analyzed to determine the spatial arrangement of specific proteins within the sample, and those specific proteins are identified as a function of the spatial arrangement. By analyzing the proteins, one may monitor and classify disease within a sample.Australia Patent 2002362961

Screening Test for ACE or Vasopeptidase Inhibitor Associated Angioedema

Angioedema is a life-threatening and unpredictable side effect of angiotensin converting enzyme (ACE) inhibitors and ACE/Neutral endopeptidase (NEP) inhibitors, drugs aimed at reducing cardiovascular mortality associated with a variety of disease states. This technology permits the identification of individuals at risk for developing this angioedemic condition as a result of taking ACE inhibitors or NEP inhibitors. The patents and patent applications claim biological markers, diagnostic methods and kits.

Methods and Compositions to Assess Oxidative Brain Injury

A method to assess oxidative stress in vivo includes the steps of measuring an amount of neuroprostanes in a biological sample before the ex vivo development of neuroprostanes in a sample, comparing the measured amount of neuroprostanes with a control and assessing oxidative stress in vivo based on this comparison. There is also provided a marker for oxidated stress by an increase of neuroprostanes in a biological sample compared to a control sample. A diagnostic tool for determining the presence of a neurodegenerative disease provides for determining an increased amount of neuroprostanes in a biological sample compared to that of a control sample.

Chemical Synthesis of Isotopically Enriched Unsaturated Precursors for Parahydrogen Induced Polarization of 15N Hyperpolarized Choline

The present invention provides unsaturated choline analogs which, when hyperpolarized, may be useful as MRI contrast agents, and methods of making these choline analogs. These analogs can also be further modified to form hyperpolarized choline for use as an MRI contrast agent. The invention takes advantage of PHIP and can be produced in volume in much shorter times than by using DNP.

Relaxation Time Discriminated 1H NMR for Bone Mechanical/Fracture Property Diagnostics

The present invention describes clinically-practical MRI methods for distinguishing bound and pore water signals from cortical bone based on T2-selective adiabatic pulses as well as T1 characteristics of cortical bone bound and pore water, and offers an improved method of assessing bone structure and fracture risk over x-ray based diagnostic techniques.

Diagnostics Management Team

The sheer volume of medical information available to physicians today is overwhelming. Diagnostic Management Team provides a concise, accurate method for ordering the correct diagnostic tests every time, and it returns the results in a uniform report format, easily read by the physician. This has already been launched within Vanderbilt University, with a high adoption rate amongst physicians and has already shown significant savings.

Method for extracting molecules from tissues

Slot-Slot Assay for Malonaldehyde-Deoxyguanosine Adducts in DNA

Gene Signature Diagnostic to Measure LKB1 Loss and MEK Inhibitor Sensitivity

A Vanderbilt research group has discovered a diagnostic to identify patients with non-small cell lung cancer that would respond to MEK inhibitor therapies. This diagnostic indirectly measures loss of tumor suppressor activity by the protein LKB1. The traditional approach to determine MEK inhibitor sensitivity, which is measurement of LKB1 mutations, misses 50% of patients who would benefit from these drugs. This diagnostic measures expression of a small panel of genes to identify a larger population that is sensitive to MEK inhibition.

Molecular Image Fusion: Cross-Modality Modeling and Prediction Software for Molecular Imaging

Featured Video

2012 Highlights

A motion graphic video describing operational improvements and successes of FY2012. Click here for a full PDF report.